Headquartered in Rockville, Innovative Cellular Therapeutics is a private clinical-stage biotechnology company developing cellular immunotherapies for solid tumors. Its proprietary CoupledCAR® platform underpins individually made CAR-T therapies, including the lead GCC19CART program being studied for relapsed or refractory metastatic colorectal cancer. Founded by Larry Lei Xiao and Zoe Zhao Wu, ICT combines more than 20 years of stem-cell, cell-therapy and gene-editing experience with FDA cellular-therapy review expertise.
Rise Therapeutics, LLCRockville-based Rise Therapeutics develops oral immunotherapies that use synthetic biology to target dendritic cells and recalibrate immune responses in autoimmune disease and cancer. The clinical-stage company pairs its proprietary oral delivery platform with in-house clinical GMP manufacturing, taking candidates from discovery through human clinical validation. Its pipeline includes oral programs for ulcerative colitis, rheumatoid arthritis, and cancer.POTOMAC, MD
MesoblastFounded in 2004 by physician-scientist Silviu Itescu, Mesoblast develops and manufactures allogeneic, off-the-shelf cellular medicines for severe inflammatory and tissue-damage conditions. Its proprietary mesenchymal lineage cell platform supports Ryoncil, the first FDA-approved mesenchymal stromal cell therapy, while the company advances additional therapies through operations in Australia, the United States and Singapore. Mesoblast’s manufacturing approach is designed for industrial-scale production of cryopreserved cell products without donor-recipient matching.NEW YORK, NY
Autolus TherapeuticsSpun out of University College London in 2014, Autolus Therapeutics develops programmed autologous CAR T-cell therapies for cancer and autoimmune diseases. The company combines T-cell programming with clinical development and a 70,000-square-foot commercial manufacturing facility in Stevenage, UK, and its pipeline includes obe-cel and other investigational therapies. Its long-running collaboration with UCL remains central to moving programs from the laboratory into clinical studies.GAITHERSBURG, MD
Tactical TherapeuticsFounded in 2005 by cancer scientist and patent attorney Rashida A. Karmali, Tactical Therapeutics is a clinical-stage biopharmaceutical company built around her long career in cancer research, drug development, and intellectual property law. The company develops CTO, an oral therapy designed to reach the brain, for patients with glioblastoma and other cancers that have resisted treatment. Karmali has authored more than 100 scientific publications and holds eight U.S. patents alongside more than 75 international patents.NEW YORK, NY